Accredited Investor email list Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for accredited investor in the search bar above.
By completing this form, you are giving consent to receive communication from Silo Wellness using the contact information you provide. And remember you can unsubscribe at any time.
Silo Wellness’ Management Team & Board of Directors
Douglas Gordon CEO (Jamaica)
Douglas Gordon is the founder of CanEx Jamaica, the premier cannabis business conference and expo in the Caribbean. He has over 30 years of experience spanning finance, media, sales and marketing. Gordon has forged a vast global network with particular attention to developing business opportunities in the Caribbean and LATAM. Gordon has developed government and distribution relations i
A bill that would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychedelics in California passed the state Senate Health Committee.
The bill will now be reviewed by the Senate Appropriations Committee, after which it would move to a Senate floor vote if approved.
SB 519 would decriminalize psilocybin, psilocyn, DMT, ibogaine, mescaline, LSD, ketamine and MDMA while expunging the criminal records of those convicted with low-level psychedelics charges.
The legislation also “sets up a working group to evaluate whether to fully legalize and regulate psychedelics in the future, and the working group will make a recommendation to the legislature,” he said.
Article content
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) Silo Wellness Inc. (“Silo Wellness” or the “Company”) (CSE: SILO) (FRA:3K70), a wellness company in the psychedelics and functional mushroom marketplaces announced today that through its wholly-owned subsidiary, it has signed a binding Letter of Intent (LOI) for a multi-year patent licensing agreement with Jungle Med Inc. (“Jungle Med”), a human health and wellness company with operations in Latin America, to exclusively manufacture, promote, advertise, distribute and sell the patent-pending, metered-dosing psilocybin nasal spray in the countries of Colombia and Brasil. This marks the Company’s first commercial transaction of its new-to-world intellectual property.